9 active not recruiting, 4 recruiting, 3 completed, 1 withdrawn. 9 Phase 2, 4 Phase 3, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 4, Completed 2, Recruiting 2, Withdrawn 1 |
| Phase 3 | 4 | Active not recruiting 3, Completed 1 |
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 4 | 1 | Recruiting 1 |
Follow Metastatic Bladder Urothelial Carcinoma: new trials by email Literature Review of Metastatic Bladder Urothelial Carcinoma trials Research Report on Metastatic Bladder Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers Best Practice, Biospecimen Collection, Central Venous Cannula Insertion - Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 70 | 2025-08-01 | 2026-05-08 |
| Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial Biospecimen Collection, Computed Tomography, Cystectomy - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma | Phase 4 | Recruiting | Mayo Clinic | 75 | 2025-01-08 | 2026-10-01 |
| Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors Biospecimen Collection, Computed Tomography, Pemetrexed - Metastatic Bladder Urothelial Carcinoma, Metastatic Malignant Solid Neoplasm | Phase 2 | Recruiting | Northwestern University | 64 | 2024-11-27 | 2026-06-12 |
| Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform Biospecimen Collection, Tissue Collection - Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma | Recruiting | Mayo Clinic | 324 | 2024-04-24 | 2026-03-12 | |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-09-22 |
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Avelumab, Biospecimen Collection, Bone Scan - Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 654 | 2022-06-03 | 2026-10-01 |
| Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Pembrolizumab, Nivolumab, Atezolizumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 3 | 2022-05-27 | 2026-03-20 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 184 | 2021-06-28 | 2026-10-22 |
| Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma Pembrolizumab, Propranolol Hydrochloride, Nivolumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | Emory University | 6 | 2021-05-20 | 2026-02-19 |
| Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy Cyclophosphamide, Fludarabine, Fludarabine Phosphate - Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2019-06-20 | 2020-01-02 | |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Carboplatin, Cisplatin, Docetaxel - Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 15 | 2019-01-11 | 2025-11-12 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-07-31 |
| Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer Berzosertib, Cisplatin, Gemcitabine Hydrochloride - Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 87 | 2017-01-31 | 2025-03-03 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Bevacizumab, Cisplatin, Gemcitabine Hydrochloride - Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 506 | 2009-07-15 | 2026-06-24 |
Urinary Bladder Neoplasms (12) · Ureteral Neoplasms (10) · Urethral Neoplasms (9) · Carcinoma, Transitional Cell (8) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasm Metastasis (2) · Prostatic Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinosarcoma (1) · Clear-cell metastatic renal cell carcinoma (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Lung Neoplasms (1)
Neoplasms (15) · Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Male Urogenital Diseases (14) · Neoplasms by Site (14) · Urogenital Diseases (14) · Urogenital Neoplasms (14) · Urologic Diseases (14) · Urologic Neoplasms (14) · Urinary Bladder Diseases (12) · Neoplasms by Histologic Type (10) · Ureteral Diseases (10) · Carcinoma (9) · Neoplasms, Glandular and Epithelial (9) · Urethral Diseases (9)
Specimen Handling (9) · pembrolizumab (6) · Magnetic Resonance Spectroscopy (5) · Nivolumab (4) · 1,2-diaminocyclohexaneplatinum II citrate (3) · Cisplatin (3) · Gemcitabine (3) · Immunoglobulin G (3) · Platinum (3) · atezolizumab (3) · avelumab (3) · enfortumab vedotin (3) · Biopsy (2) · Disulfides (2) · Docetaxel (2)
National Cancer Institute (NCI) (7) · Mayo Clinic (3) · M.D. Anderson Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Emory University (1) · Jonsson Comprehensive Cancer Center (1) · Northwestern University (1) · Roswell Park Cancer Institute (1)
United States (17) · Canada (2) · Puerto Rico (1)
Jacob J. Orme, MD, PhD (2) · Anishka A D'Souza (1) · Arnold Chin (1) · Dev Mukhopadhyay, PhD (1) · Devalingam Mahalingam (1) · Evan Y Yu (1) · Gurkamal Chatta, MD (1) · Jacqueline Brown, MD (1) · Jonathan E Rosenberg (1) · Paras H. Shah, MD (1) · Rodabe Amaria, MD (1) · Rohit Jain (1) · Sangeeta Goswami (1) · Sarmad Sadeghi (1) · Shilpa Gupta (1)
PMID 33989025, PMID 34436521, PMID 35537412, PMID 37328287, PMID 39536751, PMID 40256659, PMID 40591902, PMID 40791544, PMID 41484629
U10CA180821 (3), UM1CA186717 (2), N01CM00038 (1), P30CA015704 (1), P30CA016056 (1), P30CA060553 (1), P30CA138292 (1), U01CA154967 (1), U10CA031946 (1), U10CA180888 (1), UM1CA186644 (1), UM1CA186690 (1)